PO to IV Levothyroxine Conversion
When converting from oral to intravenous levothyroxine, use 50-75% of the oral dose due to the complete bioavailability of IV administration compared to the 40-80% absorption of oral formulations.
Conversion Rationale
The FDA labeling for Synthroid indicates that oral levothyroxine absorption from the gastrointestinal tract ranges from 40-80%, with the relative bioavailability of tablets being approximately 93% compared to oral solution 1. Since IV administration provides 100% bioavailability, a dose reduction is necessary to avoid iatrogenic hyperthyroidism.
Recommended Conversion Approach
Standard Conversion
- Reduce the oral dose by 25-50% when switching to IV 1
- For example: A patient on 100 mcg PO daily would receive 50-75 mcg IV daily
- The conservative approach (50% reduction) is safer, particularly in elderly patients or those with cardiac disease 1
Special Considerations for Myxedema Coma
For critically ill patients with myxedema coma requiring IV therapy, higher loading doses are used:
- Initial IV loading dose: 200-400 mcg (not a conversion from oral, but de novo dosing) 2
- Some protocols use 500-1000 mcg IV initially, though lower doses (500 mcg) have shown adequate clinical response within 24-72 hours 2
- After initial loading, maintenance doses of 50-100 mcg IV daily until oral intake is possible 3
Clinical Monitoring
- Peak therapeutic effect may not occur for 4-6 weeks due to levothyroxine's long half-life of 6-7 days 1
- Monitor TSH and free T4 levels, though acute changes in dosing won't be reflected immediately 1
- Watch for cardiac complications, especially in patients over 50 years or those with underlying heart disease 1
Duration of IV Therapy
Transition back to oral therapy as soon as the patient can tolerate oral medications and has normal GI absorption 3. IV levothyroxine is typically given for 3-10 days until oral administration is feasible 3.
Common Pitfalls to Avoid
- Do not use a 1:1 conversion ratio - this will result in overtreatment due to complete IV bioavailability 1
- Avoid high IV peaks - intravenous administration can cause rapid elevation of T4 and T3 to supraphysiologic levels, particularly with doses exceeding 500 mcg 2
- Consider oral alternatives first - even in critically ill patients, oral absorption may be adequate if the GI tract is functional; recent case reports show successful oral treatment even in myxedema coma 4, 5
- Account for patient-specific factors - elderly patients and those with cardiac disease require more conservative dosing, starting at the lower end of the conversion range 1
Alternative Routes When IV Unavailable
If IV levothyroxine is not available, oral liquid or crushed tablet formulations can be considered even in patients with altered consciousness or GI dysfunction, as absorption may still occur 4, 5. Rectal and intramuscular routes have been reported but are less studied 5.